Genomic Health Enters Oversold Territory (GHDX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30.

In trading on Monday, shares of Genomic Health Inc ( GHDX) entered into oversold territory, hitting an RSI reading of 29.9, after changing hands as low as $25.70 per share. By comparison, the current RSI reading of the S&P 500 ETF (SPY) is 48.7. A bullish investor could look at GHDX's 29.9 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of GHDX shares:

START SLIDESHOW:
Find out what 9 other oversold stocks you need to know about »

Genomic Health Inc 1 Year Performance Chart

Looking at the chart above, GHDX's low point in its 52 week range is $25.50 per share, with $38.99 as the 52 week high point — that compares with a last trade of $26.22.

More from Stocks

Dow Sells Off as U.S. and China Trade Tensions Escalate

Dow Sells Off as U.S. and China Trade Tensions Escalate

China Central Bank Governor Says Stay 'Calm and Rational' After Market Free Fall

China Central Bank Governor Says Stay 'Calm and Rational' After Market Free Fall

Here Is Your Market Playbook During This Tariff-Driven Selloff

Here Is Your Market Playbook During This Tariff-Driven Selloff

Dropbox Is the New Defensive Stock to Own With the Market Falling Apart

Dropbox Is the New Defensive Stock to Own With the Market Falling Apart

The Quick Answer Why Trump's Trade War Makes Stocks at Least 10% Overvalued

The Quick Answer Why Trump's Trade War Makes Stocks at Least 10% Overvalued